Medium impact
2025 August Medical Policy Updates
BlueCross BlueShield of South Carolina·Effective Aug 28, 2025
HCPCS S3844 is officially defined as "Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness." HCPCS S3844 is referenced in 1 tracked payer policy change from BlueCross BlueShield of South Carolina. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS S3844 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.